Literature DB >> 96734

SK&F 75073, new parenteral broad-spectrum cephalosporin with high and prolonged serum levels.

P Actor, J V Uri, I Zajac, J R Guarini, L Phillips, D H Pitkin, D A Berges, G L Dunn, J R Hoover, J A Weisbach.   

Abstract

SK&F 75073, a new parenteral cephalosporin, was found to have broad in vitro and in vivo antibacterial activity including isolates usually resistant to cephalothin and cefazolin. This activity included indole-positive Proteus and Enterobacter species and some Serratia isolates. Proteus mirabilis strains were particularly susceptible, as were Haemophilus influenzae and Neisseria species. The activity of SK&F 75073 against gram-positive bacteria was poorer than that of the control cephalosporins. This cephalosporin is highly bound to serum proteins, and a loss in in vitro activity was observed in the presence of serum. Parenteral administration of SK&F 75073 to experimental animals (mice, dogs, squirrel monkeys) resulted in high and prolonged serum levels when compared with cefazolin and other injectable cephalosporins. This favorable serum profile was reflected in the excellent protection observed in mice infected with pathogenic bacteria.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 96734      PMCID: PMC352331          DOI: 10.1128/AAC.13.5.784

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  BL-S786, a new parenteral cephalosporin. I. A collaborative in vitro susceptibility comparison to cephalothin against 5,762 clinical bacterial isolates.

Authors:  R N Jones; P C Fuchs; T L Gavan; E H Gerlach; A Barry; C Thornsberry
Journal:  J Antibiot (Tokyo)       Date:  1977-07       Impact factor: 2.649

2.  Susceptibility of Enterobacter to cefamandole: evidence for a high mutation rate to resistance.

Authors:  C M Findell; J C Sherris
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

3.  Cefuroxime, a new cephalosporin antibiotic: activity in vitro.

Authors:  C H O'Callaghan; R B Sykes; A Griffiths; J E Thornton
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

4.  Laboratory studies with cefatrizine (SK + F 60771), a new broad-spectrum orally-active cephalosporin.

Authors:  P Actor; J V Uri; L Phillips; C S Sachs; J R Guarini; I Zajac; D A Berges; G L Dunn; J R Hoover; J A Weisbach
Journal:  J Antibiot (Tokyo)       Date:  1975-08       Impact factor: 2.649

5.  Laboratory evaluation of BL-S786, a cephalosporin with broad-spectrum antibacterial activity.

Authors:  F Leitner; M Misiek; T A Pursiano; R E Buck; D R Chisholm; R G DeRegis; Y H Tsai; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

6.  Cefoxitin, a semisynthetic cephamycin antibiotic: in vivo evaluation.

Authors:  A K Miller; E Celozzi; Y Kong; B A Pelak; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

7.  Disk susceptibility studies with cefazolin and cephalothin.

Authors:  P Actor; J Guarini; J Uri; J Dickson; J F Pauls; J A Weisbach
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

8.  Biological properties of three 3-heterocyclic-thiomethyl cephalosporin antibiotics.

Authors:  W E Wick; D A Preston
Journal:  Antimicrob Agents Chemother       Date:  1972-03       Impact factor: 5.191

9.  Cefoxitin, a semisynthetic cephamycin antibiotic: resistance to beta-lactamase inactivation.

Authors:  H R Onishi; D R Daoust; S B Zimmerman; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

10.  Antibacterial activity of cefamandole, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cephalexin.

Authors:  S Eykyn; C Jenkins; A King; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1973-06       Impact factor: 5.191

View more
  18 in total

1.  Effect of age and renal function on cefonicid pharmacokinetics.

Authors:  J M Trang; T P Monson; B H Ackerman; F L Underwood; J T Manning; G L Kearns
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

2.  Antistaphylococcal activity of ceforanide and cefonicid in the presence of human serum.

Authors:  A L Barry; R N Jones; R R Packer
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

3.  Peritoneal transport of cefonicid.

Authors:  G D Morse; T Lane; D K Nairn; J Deterding; J Curry; P Gal
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

4.  Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin.

Authors:  S L Barriere; G J Hatheway; J G Gambertoglio; E T Lin; J E Conte
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

5.  Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys.

Authors:  H Matsui; K Yano; T Okuda
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

Review 6.  Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  E Saltiel; R N Brogden
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

7.  Cefonicid versus clindamycin prophylaxis for head and neck surgery in a randomized, double-blind trial, with pharmacokinetic implications.

Authors:  D Swanson; R A Maxwell; J T Johnson; R L Wagner; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

8.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

9.  Plasma and myocardial levels of cefonicid during open-heart surgery.

Authors:  R P Sterling; D J Connor; J C Norman
Journal:  J Natl Med Assoc       Date:  1983-11       Impact factor: 1.798

10.  Precipitate formation of some sulfonated tetrazolthiomethyl cephalosporins with basic chemicals.

Authors:  J V Uri; P Actor
Journal:  Experientia       Date:  1982-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.